文献速递膀胱癌与上尿路尿路上皮癌

基于B细胞基因特征表达的免疫检查点抑制剂治疗生存的性别分层

Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature.
PubMed 文献 · Eur Urol Oncol · 2021-08-21

研究分析IMvigor 210试验中348例晚期尿路上皮癌患者和TCGA中406例肌层浸润性膀胱癌患者的肿瘤RNA测序数据,探讨B细胞基因特征(BCGS)与免疫检查点抑制剂(ICI)治疗后总生存(OS)的关系。结果显示B8T高/高肿瘤在ICI治疗的男性中与最佳临床结局相关,但在女性中未与更好OS相关;相反,在未接受ICI治疗的肌层浸润性膀胱癌女性中B8T高/高肿瘤与最佳临床结局相关。提示B8T特征可增强ICI治疗晚期尿路上皮癌患者的OS分层,肿瘤免疫微环境的性别差异可能导致不同结局。

要点

  • B8T高/高肿瘤在ICI治疗的男性中与最长OS相关,女性中未显示更好OS。
  • B8T特征可将高TMB或高PD-L1患者进一步分层为不同OS亚组。
  • 未接受ICI治疗的肌层浸润性膀胱癌女性中B8T高/高与最佳结局相关。

核心结论

  • B8T特征可增强ICI治疗晚期尿路上皮癌患者的OS分层。
  • 肿瘤免疫微环境的性别差异可能导致不同结局。

研究设计与样本

  • 回顾性分析IMvigor 210二期临床试验中348例接受阿替利珠单抗治疗的晚期尿路上皮癌患者。
  • 纳入TCGA中406例肌层浸润性膀胱癌患者。
  • 分析肿瘤RNA测序数据,探讨BCGS与临床结局的关系。

主要发现

  • B细胞和CD8+ T细胞基因特征高表达(B8T高/高)的肿瘤在所有B8T组中与最长OS相关。
  • B8T特征可将高肿瘤突变负荷或高PD-L1肿瘤患者分层为不同OS亚组。
  • ICI治疗的男性中B8T高/高肿瘤与最佳临床结局相关,女性中未与更好OS相关。
  • 未接受ICI治疗的肌层浸润性膀胱癌女性中B8T高/高肿瘤与最佳临床结局相关。

临床怎么用

  • B8T特征可能用于ICI治疗晚期尿路上皮癌患者的OS分层。
  • 性别差异提示需考虑性别特异的免疫微环境制定治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a great need to identify biomarkers that can accurately identify patients who will obtain the most clinical benefit from immune checkpoint inhibitor (ICI) therapy. While high intratumoral B cell gene expression correlated with an ICI response in melanoma, whether it adds predictive value in other cancers is unknown. OBJECTIVE: To examine the relationship between B cell gene signature (BCGS) expression and overall survival (OS) following ICI treatment. DESIGN, SETTING, AND PARTICIPANTS: A total of 348 patients with advanced urothelial carcinoma from the IMvigor 210 phase 2 clinical trial of atezolizumab and 406 patients with muscle-invasive bladder cancer from The Cancer Genome Atlas (TCGA) were included. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We analyzed tumor RNA sequencing data of included patients to examine the relationships between a BCGS and clinical outcomes. RESULTS AND LIMITATIONS: Tumors with high levels of B cell and CD8+ T cell gene signatures (BCGS/CD8TGS or B8T high/high) were associated with the longest OS of all B8T groups. Moreover, the B8T cell signature stratified patients whose tumors had a high tumor mutational burden or high programmed death ligand 1 (PD-L1) into subsets with differential OS outcomes. Whereas the B8T high/high tumors were associated with the best clinical outcomes in ICI-treated men, they were not associated with better OS in women. Conversely, women with B8T high/high tumors had the best clinical outcomes in non-ICI-treated muscle-invasive bladder cancer. CONCLUSIONS: These data suggest that the B8T signature can enhance OS stratification in patients with advanced urothelial carcinoma who are treated with ICI therapy and that sex-specific differences in the tumor immune microenvironment may drive disparate outcomes. PATIENT SUMMARY: We examined whether the presence of two immune cell gene signatures within tumor samples impact survival in patients with bladder cancer. High levels of both of these signatures (B cells and CD8+ T cells) associate with superior survival in patients who receive immune therapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Aragaki AK, Jing Y, Hoffman-Censits J, et al. Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature. Eur Urol Oncol. 2021. PMID: 34426176. doi:10.1016/j.euo.2021.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。